Arcadia Biosciences FY2022 revenue up 47% to $9.96M; net loss per share improves to $25.65 from $27.56

Arcadia Biosciences, Inc.

Total revenues $9.956M, up 47% YoY; Q4 revenue $1.0M, down 54% YoY.
Operating expenses $28.771M, down 32% YoY; cash used in operations $13.977M, down 46%.
Net loss attributable to common stockholders $15.376M ($25.65/share) vs $14.660M ($27.56/share) in 2021.
GoodWheat pasta launched in Q2 2022, reached 1,200+ stores within 7 months; AHA Heart-Check certified.
CEO Stan Jacot appointed in Q1 2022; Project Greenfield 3-year plan for profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcadia Biosciences, Inc. reported financial results for fourth quarter and year ended December 31, 2022.

Period: fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.